Evolving practices in pretransplant cardiovascular screening: moving toward personalized assessments
- 1Marmara University, Faculty of Medicine, Department of Nephrology, Istanbul, Turkiye.
- 2Marmara University, Faculty of Medicine, Department of Cardiology, Istanbul, Turkiye.
Abstract
Cardiovascular (CV) disease remains the leading cause of morbidity and mortality in patients with end-stage kidney disease, including those evaluated for kidney transplantation. Pretransplant CV screening has traditionally focused on detecting occult coronary artery disease and guiding revascularization to reduce perioperative risk. However, emerging evidence, most notably from the ISCHEMIA-CKD trial, has challenged this paradigm, demonstrating no clear benefit of routine invasive strategies or prophylactic revascularization in stable, asymptomatic patients over optimal medical therapy. Risk assessment in kidney transplant candidates should rely on an integrated clinical evaluation that incorporates symptoms, functional capacity, baseline electrocardiography and echocardiographic findings, and the presence of major CV risk factors. When further evaluation is indicated, stress echocardiography is generally preferred as the noninvasive modality. Invasive coronary angiography should be reserved for patients with cardiac symptoms or findings suggestive of significant ischemia, including reduced left ventricular ejection fraction, regional wall motion abnormalities, or moderate-to-large ischemia on stress testing. Pre-emptive revascularization should be limited to established guideline-based indications, such as left main disease, multivessel disease with reduced ejection fraction, or refractory angina despite optimal medical therapy. Noncoronary CV disorders, including heart failure, valvular disease, and pulmonary hypertension, require systematic assessment and cardiology referral. In conclusion, pretransplant CV assessment is shifting from protocol-driven screening toward individualized, clinical suspicion-based evaluation, prioritizing optimal medical therapy, avoidance of unnecessary testing, and timely access to transplantation.
Related
- Toward personalized and longitudinal antibiograms--a proof-of-concept for in vivo assessments of immunological-antibiotic-bacterial interactions
- Trends and Factors Associated with LDL-C Treatment Target Attainment Rates among Patients with Secondary Prevention Setting of Atherosclerotic Cardiovascular Disease: Assessments from Japanese Health Checkup Data
- DRFAS-enhanced personalized federated learning for secure and robust cardiovascular disease detection
- Personalized Prevention of Cardiovascular Diseases Through Measurement of Plaque Burden in the Carotid Artery
- Pharmacogenomics-guided cardiovascular therapy in low- and middle-income countries: A systematic review of barriers, equity gaps, and pathways to personalized medicine
BibTeX
@article{velioglu2026evolving,
title = {{Evolving practices in pretransplant cardiovascular screening: moving toward personalized assessments}},
author = {Arzu Velioglu and Tansu Celik and Harun Coban and Dilek Barutcu Atas and Altug Cincin and Serhan Tuglular},
journal = {Clinical kidney journal},
year = {2026},
month = jul,
doi = {10.1093/ckj/sfag225},
url = {https://europepmc.org/article/PMC/PMC13716674},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Evolving practices in pretransplant cardiovascular screening: moving toward personalized assessments
AU - Arzu Velioglu
AU - Tansu Celik
AU - Harun Coban
AU - Dilek Barutcu Atas
AU - Altug Cincin
AU - Serhan Tuglular
PY - 2026
DA - 2026/07/10
JO - Clinical kidney journal
DO - 10.1093/ckj/sfag225
UR - https://europepmc.org/article/PMC/PMC13716674
AB - Cardiovascular (CV) disease remains the leading cause of morbidity and mortality in patients with end-stage kidney disease, including those evaluated for kidney transplantation. Pretransplant CV screening has traditionally focused on detecting occult coronary artery disease and guiding revascularization to reduce perioperative risk. However, emerging evidence, most notably from the ISCHEMIA-CKD trial, has challenged this paradigm, demonstrating no clear benefit of routine invasive strategies or prophylactic revascularization in stable, asymptomatic patients over optimal medical therapy. Risk assessment in kidney transplant candidates should rely on an integrated clinical evaluation that incorporates symptoms, functional capacity, baseline electrocardiography and echocardiographic findings, and the presence of major CV risk factors. When further evaluation is indicated, stress echocardiography is generally preferred as the noninvasive modality. Invasive coronary angiography should be reserved for patients with cardiac symptoms or findings suggestive of significant ischemia, including reduced left ventricular ejection fraction, regional wall motion abnormalities, or moderate-to-large ischemia on stress testing. Pre-emptive revascularization should be limited to established guideline-based indications, such as left main disease, multivessel disease with reduced ejection fraction, or refractory angina despite optimal medical therapy. Noncoronary CV disorders, including heart failure, valvular disease, and pulmonary hypertension, require systematic assessment and cardiology referral. In conclusion, pretransplant CV assessment is shifting from protocol-driven screening toward individualized, clinical suspicion-based evaluation, prioritizing optimal medical therapy, avoidance of unnecessary testing, and timely access to transplantation.
SN - 2048-8505
SN - 2048-8513
ER -